Bacteriophages are viruses that solely ... fibrosis who experience chronic P aeruginosa infections. Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for ...

According to a new report, Bacteriophage Therapy Market will grow from US$ 1,280.9 million in 2023 to US$ 1,651.8 million by 2030 at a compounded annual growth rate (CAGR) of 3.7% during the forecast ...

The company, which secured $200 million from investors in a private funding deal last week, learned Tuesday of a serious side effect experienced by one participant on a high dose of its Rett therapy.

The growing demand for personalized medicine and advancements in phage therapy research are further driving industry growth. Scientists and healthcare professionals are increasingly exploring ...

Bacteriophages, or phages, are viruses that specifically infect bacteria. With the rise of antibiotic-resistant infections, there has been a renewed interest in phage therapy as a potential ...

Returning to Boston this February, the Bacteriophage Therapy Summit is the only global platform for industry-dominated phage drug developers. Uniting 90+ Chief Executive Officers, Vice Presidents ...

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 inhibitor therapy.

Scientists looked at multiple techniques used to measure the modified viruses deployed in some gene therapy research and treatments. One technique, known as SEC-MALS, was the most precise and ...

Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?

The one-off gene therapy, known as exagamglogene autotemcel (or ‘exa-cel’), has been approved for use on the NHS in England from today (Friday 31 January) by the National Institute for Health and Care ...

Asiawu Imam says the therapy will make a huge difference A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England.

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.